PSC
ALNY icon

Portman Square Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Portman Square Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.53M Buy
25,016
+8,092
+48% +$2.44M 0.36% 58
2026
Q1 		$5.6M Buy
16,924
+14,467
+589% +$4.92M 0.22% 75
2025
Q4 		$977K Buy
+2,457
New +$1.09M 0.04% 109
2025
Q3 		– Sell
-6,967
Closed -$2.84M – 110
2025
Q2 		$2.27M Sell
6,967
-5,562
-44% -$1.54M 0.07% 149
2025
Q1 		$3.38M Sell
12,529
-410
-3% -$105K 0.09% 175
2024
Q4 		$3.04M Buy
12,939
+4,426
+52% +$1.16M 0.11% 152
2024
Q3 		$2.34M Sell
8,513
-3,335
-28% -$868K 0.09% 210
2024
Q2 		$2.88M Sell
11,848
-4,175
-26% -$659K 0.1% 205
2024
Q1 		$2.39M Buy
16,023
+10,060
+169% +$1.68M 0.07% 192
2023
Q4 		$1.14M Sell
5,963
-5,951
-50% -$1.01M 0.03% 344
2023
Q3 		$2.11M Buy
11,914
+2,146
+22% +$409K 0.05% 295
2023
Q2 		$1.86M Buy
9,768
+4,876
+100% +$967K 0.05% 252
2023
Q1 		$980K Buy
+4,892
New +$1.03M 0.05% 214

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Portman Square Capital's ALNY Position: Q2 2026 in Review

Portman Square Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 48% in Q2 2026, buying an estimated $2.44M and bringing the position to 25,016 shares worth $7.53M. The position accounts for 0.36% of the portfolio, ranked #58.

Portman Square Capital first reported a position in ALNY in Q1 2023 and has held it in 13 quarters since. 102 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Portman Square Capital held 25,016 shares of Alnylam Pharmaceuticals worth $7.53M as of Q2 2026.
  • Portman Square Capital bought 8,092 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.44M.
  • Alnylam Pharmaceuticals made up 0.36% of Portman Square Capital's portfolio in Q2 2026, its #58 holding.
  • Portman Square Capital first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 102 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Portman Square Capital's 13F filing for Q2 2026, filed 15 Jul 2026.